qXR-LN
K231805Qure.ai Technologies · cleared 2023-12-22 · product code MYN · Radiology
Premarket evidence — what FDA accepted
source quote (p.8)
“The qXR-LN is a software only device, similar to the predicate (Samsung Auto Lung Nodule Detection).”
source quote (p.5)
“The device utilizes a deep learning algorithm.”
Validation studies (2)
Retrospective clinical
sample size not stated · 40 site(s)
endpoints: nodule-level sensitivity; overall FPPI; scan level AUC; Sensitivity; specificity
Reader study (MRMC)
sample size not stated
endpoints: AFROC Estimate; AFROC (aided-unaided); P - Value; AUC; nodule level sensitivity
Reported performance (5 observations)
source quote (p.7)
“Nodule level sensitivity 84.10 (77.97-97.24)”
source quote (p.7)
“Sensitivity of 93.83 (88.94 – 97) and specificity of 81.09 (76.30 – 85) was achieved.”
source quote (p.7)
“qXR-LN achieved a scan level AUC of 94.51 (92.64 - 96.66).”
source quote (p.7)
“Nodule level Sensitivity (aided - unaided) 11.96”
source quote (p.8)
“The AUC of the readers improved by an estimate of 0.0697 (0.442 – 0.0953)”
Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.
Predicate network
Postmarket — what happened after clearance
- re_clearance
The FDA AI/ML device list shows a newer 510(k) K251934 (decision 2026-01-16) from Qure.Ai Technologies for a matching device line ("qXR-Detect") — a new clearance for the same line is a change event. The newer clearance's parsed summary mentions a PCCP.
first seen 2026-07-08 · k_number:K251934
Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.
Reimbursement — how devices like this got paid
Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).